New Phase 3 data showed the antibody‑drug conjugate Padcev (enfortumab vedotin) combined with Merck’s Keytruda (pembrolizumab) extended survival in locally advanced or metastatic bladder cancer compared with prior standards, the ESMO presentations reported. Sponsors highlighted the confirmatory nature of the trial and the potential to expand the combination into broader labels for urothelial carcinoma. The data reinforce the growing role of ADC‑checkpoint inhibitor combinations across genitourinary oncology.